Quarterly ResultAug 13, 2026, 04:13 PM
Sunshine Biopharma Q2 Revenue $9.26M; Net Loss $(1.56M)
AI Summary
Sunshine Biopharma Inc. reported a Q2 2026 revenue of $9.26 million, a slight decrease from $9.41 million in Q2 2025. The company's net loss for the quarter improved to $(1.56) million from $(1.77) million year-over-year, with basic loss per share improving to $(1.15) from $(3.94). For the six months ended June 30, 2026, the company raised $7.80 million from financing activities, significantly boosting its cash and cash equivalents to $13.75 million. The company also settled a legal dispute for $1.06 million and initiated an At-The-Market offering to raise additional capital.
Key Highlights
- Q2 2026 Revenue decreased 1.56% to $9.26 million from $9.41 million YoY.
- Q2 2026 Net Loss improved to $(1.56) million from $(1.77) million YoY.
- Basic Loss per Share for Q2 2026 improved to $(1.15) from $(3.94) YoY.
- Cash and cash equivalents increased to $13.75 million as of June 30, 2026.
- Net cash provided by financing activities was $7.80 million for YTD 2026.
- Settled a legal dispute for $1.06 million in July 2026.
- Initiated an ATM offering for up to $4.0 million, selling $1.72 million by August 12, 2026.
- Total assets increased to $33.63 million from $30.08 million since Dec 31, 2025.
Price Impact
More from SBFM